novo nordisk denmark - Search News

Novo Nordisk to cap insulin prices in Minnesota settlement

Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.

MinnPost · 1d

AG Ellison settles with Novo Nordisk to cap out-of-pocket payments for insulin at $35 a month

Minnesota A.G. Keith Ellison says his office settled with Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month.

Reuters on MSN · 1d

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

KARE-TV Minneapolis-St. Paul o… · 1d

Novo Norodisk caps insulin prices at $35 for Minnesotans

If you rely on insulin, you will be able to buy Novo Nordisk's products for $35 per month due to a settlement announced Monday.

Novo Nordisk’s Ozempic Gets FDA Approval

U.S. News & World Report · 17h

US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic Kidney Disease Progression

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

Hosted on MSN · 16h

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

CNBC on MSN · 17h

FDA approves Novo Nordisk’s diabetes drug Ozempic for chronic kidney disease, expanding its use

Ozempic's expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

U.S. News & World Report13d

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats

including CEO of obesity drugmaker Novo Nordisk, met with the government. Denmark's Prime Minister Mette Frederiksen ...

PharmiWeb2d

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

UBS Remains a Buy on Novo Nordisk (0QIU)

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

4don MSN

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

The Pharma Letter4d

Novo Nordisk jumps on positive early trial with SC amycretin for obesity

Denmark’s Novo Nordisk saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results ...

Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Novo Nordisk A/S - share repurchase programme

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...

12h

LVMH reports muted sales amid hope that the luxury downturn might finally be ending

I’m not going to report record revenue, but it was nonetheless a robust year," CEO Bernard Arnault said during the earnings ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results